Clinical Trial Update: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two dosing regimens of obinutuzumab in previously untreated chronic lymphocytic leukemia; the study (GAGE) is completed and results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Obinutuzumab (RO5072759; GA101) (obinutuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lymphocytic Leukemia, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2014-04-24